Psychosis is a common neuropsychiatric symptom of Parkinson’s disease, and can serve as a clinical marker of advanced disease. Our study aimed to investigate the characteristics of psychosis in a longitudinal PD cohort, to verify baseline clinical risk factors for future psychotic symptoms in de novo PD patients, and to evaluate the relationship between baseline gray matter density in the nucleus basalis of Meynert and future psychotic symptoms in PD. We found lower NBM density at baseline to be associated with increased psychotic symptom burden compared to controls, suggesting utility for the NBM as a neuroimaging biomarker for advanced PD.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords